Literature DB >> 1138675

Reversible nephrotoxicity associated with cephalothin therapy.

D P Pasternak, B G Stephens.   

Abstract

A 53-year-old man with scalp cellulitis developed acute renal failure after sodium cephalothin therapy. The patient probably had preexisting renal disease. Discontinuance of cephalothin was followed by improvement of the renal function. Specimens from a renal biopsy performed during the recovery phase showed nonspecific changes in the renal tubular epithelium, similar to those seen in animals treated with large doses of cephalothin. Previously reported cases of cephalothin nephrotoxicity, along with this case, caution the clinician to proceed with care in the treatment of azotemic patients with cephalothin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138675

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

2.  Protective effect of cephalothin against gentamincin-induced nephrotoxicity in rats.

Authors:  P Dellinger; T Murphy; V Pinn; M Barza; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

3.  High-performance liquid chromatographic method for determination of cefmetazole in human serum.

Authors:  M Sekine; K Sasahara; T Kojima; T Morioka
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

4.  Quantitation of antibiotics by high-pressure liquid chromatography: cephalothin.

Authors:  I Nilsson-Ehle; T T Yoshikawa; M C Schotz; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

5.  Effects of various cephalosporins on the proximal tubule of the human kidney.

Authors:  A W Mondorf; M Zegelman; J Klose; L Maske; J E Scherberich; T Stefanescu; H Müller; W Schoeppe
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.